Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with
uterine cancer that has come back or has not responded to treatment. Pazopanib hydrochloride
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Pazopanib hydrochloride may also stop the growth of uterine cancer by blocking blood flow to
the tumor.